George I. Papakostas
#161,228
Most Influential Person Now
George I. Papakostas's AcademicInfluence.com Rankings
George I. Papakostasphilosophy Degrees
Philosophy
#9307
World Rank
#12846
Historical Rank
Logic
#6288
World Rank
#7796
Historical Rank
Download Badge
Philosophy Biology
Why Is George I. Papakostas Influential?
(Suggest an Edit or Addition)George I. Papakostas's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- [Detection, evaluation, and treatment of high blood cholesterol in adults]. (2001) (1117)
- Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. (2009) (415)
- Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD (2009) (343)
- Treatment-resistant depression. (2006) (326)
- Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents (2007) (294)
- Quality of life assessments in major depressive disorder: a review of the literature. (2004) (293)
- Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. (2016) (292)
- S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. (2010) (273)
- A detailed examination of cytokine abnormalities in Major Depressive Disorder (2008) (273)
- Treatment of SSRI-Resistant Depression: A Meta-Analysis Comparing Within- Versus Across-Class Switches (2008) (249)
- L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. (2012) (228)
- Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. (2007) (223)
- Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. (2011) (207)
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD) (2018) (203)
- A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. (2006) (198)
- Tolerability of modern antidepressants. (2008) (172)
- A Double‐Blind, Randomized, Pilot Dose‐Finding Study of Maca Root (L. Meyenii) for the Management of SSRI‐Induced Sexual Dysfunction (2008) (171)
- Dopaminergic-based pharmacotherapies for depression (2006) (162)
- Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a Pilot and Replication Study (2013) (160)
- Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. (2004) (159)
- Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses (2004) (146)
- Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice (2009) (145)
- Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. (2004) (140)
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. (2021) (137)
- RELATIONSHIP BETWEEN SLEEP DISTURBANCE AND DEPRESSION, ANXIETY, AND FUNCTIONING IN COLLEGE STUDENTS (2013) (137)
- Resolution of Sleepiness and Fatigue in Major Depressive Disorder: A Comparison of Bupropion and the Selective Serotonin Reuptake Inhibitors (2006) (137)
- Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice. (2014) (130)
- Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. (2009) (129)
- Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. (2005) (126)
- A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. (2014) (119)
- Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. (2004) (119)
- Empirical Testing of Two Models for Staging Antidepressant Treatment Resistance (2005) (111)
- Effects of smartphone use with and without blue light at night in healthy adults: A randomized, double-blind, cross-over, placebo-controlled comparison. (2017) (111)
- Symptoms of fatigue and sleepiness in major depressive disorder. (2006) (110)
- A Meta-Analysis of Early Sustained Response Rates Between Antidepressants and Placebo for the Treatment of Major Depressive Disorder (2006) (109)
- Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. (2014) (107)
- Augmentation of antidepressants with atypical antipsychotics for treatment‐resistant major depressive disorder (2008) (106)
- S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. (2014) (104)
- Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary meta-analysis (2010) (102)
- Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. (2009) (101)
- S-Adenosyl-L-Methionine (SAMe) as an Adjunct for Resistant Major Depressive Disorder: An Open Trial Following Partial or Nonresponse to Selective Serotonin Reuptake Inhibitors or Venlafaxine (2004) (100)
- Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. (2008) (100)
- Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder (2008) (99)
- Lithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants (2003) (94)
- A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. (2009) (94)
- Obesity among outpatients with major depressive disorder. (2005) (93)
- S-adenosyl-methionine in depression: A comprehensive review of the literature (2003) (92)
- Nortriptyline for treatment-resistant depression. (2003) (91)
- The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. (2005) (90)
- A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder (2008) (90)
- Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder (2015) (86)
- Folates and S-Adenosylmethionine for Major Depressive Disorder (2012) (85)
- Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. (2004) (78)
- Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis. (2012) (77)
- Reduced orbitofrontal-thalamic functional connectivity related to suicidal ideation in patients with major depressive disorder (2017) (71)
- Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. (2011) (68)
- Reduced frontal-subcortical white matter connectivity in association with suicidal ideation in major depressive disorder (2016) (67)
- International consensus statement on major depressive disorder. (2010) (67)
- An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. (2005) (66)
- The efficacy, tolerability, and safety of contemporary antidepressants. (2010) (65)
- Psychosocial Functioning During the Treatment of Major Depressive Disorder With Fluoxetine (2004) (64)
- A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder (2008) (64)
- Cardiovascular Risk Factors May Moderate Pharmacological Treatment Effects in Major Depressive Disorder (2005) (62)
- HOPELESSNESS AND SUICIDAL IDEATION IN OUTPATIENTS WITH TREATMENT-RESISTANT DEPRESSION: PREVALENCE AND IMPACT ON TREATMENT OUTCOME (2003) (61)
- Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. (2002) (61)
- Resolution of sleepiness and fatigue: A comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union (2014) (59)
- The combination of duloxetine and bupropion for treatment‐resistant major depressive disorder (2006) (59)
- Somatic symptoms in treatment-resistant depression (2003) (58)
- Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. (2011) (58)
- Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. (2010) (57)
- Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. (2004) (57)
- MDDScore: confirmation of a blood test to aid in the diagnosis of major depressive disorder. (2015) (54)
- A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder (2007) (54)
- Low-dose Transdermal Testosterone Augmentation Therapy Improves Depression Severity in Women (2009) (51)
- The nature of placebo response in clinical studies of major depressive disorder. (2015) (50)
- Brain white-matter hyperintensities and treatment outcome in major depressive disorder (2006) (50)
- Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. (2006) (47)
- Experimental medication treatment approaches for depression (2017) (47)
- A meta-analysis of clinical trials comparing milnacipran, a serotonin–norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder (2007) (47)
- Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group. (2011) (47)
- The pro-inflammatory profile of depressed patients is (partly) related to obesity. (2015) (46)
- Serum Cholesterol in Treatment-Resistant Depression (2003) (45)
- Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study. (2015) (45)
- Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder (2008) (45)
- Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. (2020) (44)
- A Metaanalysis of Clinical Trials Comparing Moclobemide with Selective Serotonin Reuptake Inhibitors for the Treatment of Major Depressive Disorder (2006) (44)
- Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. (2006) (44)
- Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II) (2005) (44)
- Extreme response style in recurrent and chronically depressed patients: change with antidepressant administration and stability during continuation treatment. (2007) (43)
- Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies (2009) (41)
- Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. (2008) (40)
- Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. (2015) (40)
- NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients (2002) (40)
- Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine (2010) (39)
- Severe and anxious depression: Combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors (2012) (39)
- Major depressive disorder: psychosocial impairment and key considerations in functional improvement. (2009) (38)
- Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials (2011) (38)
- Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder (2010) (38)
- Psychosocial functioning in patients with treatment resistant depression (2004) (37)
- Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. (2003) (37)
- Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome (2010) (37)
- Limitations of contemporary antidepressants: tolerability. (2007) (36)
- Serum cholesterol and serotonergic function in major depressive disorder (2003) (36)
- Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. (2004) (35)
- Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. (2019) (34)
- Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram (2011) (34)
- Anger Attacks in Major Depressive Disorder and Serum Levels of Homocysteine (2006) (33)
- Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. (2012) (33)
- Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine (2004) (33)
- Treatment of Major Depressive Disorder and Dysthymic Disorder With Antidepressants in Patients With Comorbid Opiate Use Disorders Enrolled in Methadone Maintenance Therapy: A Meta-Analysis (2011) (33)
- Escitalopram Versus SNRI Antidepressants in the Acute Treatment of Major Depressive Disorder: Integrative Analysis of Four Double-Blind, Randomized Clinical Trials (2009) (33)
- Is S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males? A Re-Analysis of Data from a Randomized Clinical Trial (2015) (32)
- Treatment-Resistant Depression and Axis II Comorbidity (2002) (32)
- An overview of vortioxetine. (2014) (31)
- Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment‐resistant depression (2018) (31)
- Adjunctive atomoxetine for residual fatigue in major depressive disorder. (2006) (30)
- Timing of Clinical Improvement and Symptom Resolution in the Treatment of Major Depressive Disorder (2008) (30)
- Understanding and managing Cognition in the Depressed Patient. (2015) (30)
- Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I) (2005) (29)
- Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine. (2006) (29)
- Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder (2007) (29)
- SAMe and sexual functioning (2012) (29)
- Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. (2018) (28)
- Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder. (2012) (28)
- Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender–age interactions (2007) (27)
- Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies. (2013) (27)
- Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials. (2007) (27)
- Axis III disorders in treatment-resistant major depressive disorder (2003) (26)
- Antidepressant Dose Reduction and the Risk of Relapse in Major Depressive Disorder (2007) (26)
- Surrogate markers of treatment outcome in major depressive disorder. (2012) (26)
- Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder (2004) (25)
- A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. (2012) (25)
- Antidepressants and their effect on cognition in major depressive disorder. (2015) (25)
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). (2019) (24)
- Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder. (2005) (24)
- Pharmacotherapy for Depression and Treatment-Resistant Depression (2010) (24)
- Switching to bupropion in fluoxetine-resistant major depressive disorder. (2003) (23)
- Behavioral and Emotional Disturbances in the Offspring of Depressed Parents with Anger Attacks (2003) (23)
- Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach. (2011) (23)
- Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder (2012) (22)
- Predictors of placebo response in bipolar depression (2015) (22)
- Heart rate variability for treatment response between patients with major depressive disorder versus panic disorder: A 12-week follow-up study. (2019) (21)
- Use of atypical antipsychotics for treatment-resistant major depressive disorder (2008) (20)
- Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. (2012) (20)
- Long-term efficacy, safety, and tolerability of L-methylfolate calcium 15 mg as adjunctive therapy with selective serotonin reuptake inhibitors: a 12-month, open-label study following a placebo-controlled acute study. (2016) (20)
- Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder. (2007) (20)
- Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. (2003) (19)
- Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder? (2012) (19)
- A survey of prescribing preferences in the treatment of refractory depression: recent trends. (2001) (19)
- Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response. (2018) (18)
- Diagnosis of co-morbid axis-I psychiatric disorders among women with newly diagnosed, untreated endocrine disorders (2010) (18)
- Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. (2020) (18)
- Relationship between placebo response rate and clinical trial outcome in bipolar depression. (2016) (17)
- Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset. (2021) (17)
- Tachyphylaxis in major depressive disorder: A review of the current state of research. (2019) (17)
- Predictive inflammatory biomarkers for change in suicidal ideation in major depressive disorder and panic disorder: A 12-week follow-up study. (2020) (16)
- Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment (2012) (16)
- Clinical characteristics of depressed patients with comorbid diabetes mellitus (2006) (16)
- Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment. (2010) (15)
- Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder (2016) (15)
- Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: A meta-analysis (2010) (14)
- Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD) (2018) (14)
- Deformities of the Globus Pallidus are Associated with Severity of Suicidal Ideation and Impulsivity in Patients with Major Depressive Disorder (2019) (14)
- Impact of Supplementation and Nutritional Interventions on Pathogenic Processes of Mood Disorders: A Review of the Evidence (2021) (14)
- Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder. (2004) (14)
- Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression (2018) (14)
- Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine (2010) (14)
- The Role of Cognitive-Behavioral Therapy and Fluoxetine in Prevention of Recurrence of Major Depressive Disorder (2010) (14)
- Substance dependence. (1998) (13)
- Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder (2020) (13)
- A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder (2019) (13)
- A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. (2005) (13)
- Current Trends in Identifying Rapidly Acting Treatments for Depression (2016) (13)
- Updates and trends in the treatment of major depressive disorder. (2014) (12)
- Cost-Effectiveness of Adjunctive Therapy with Atypical Antipsychotics for Acute Treatment of Major Depressive Disorder (2012) (12)
- Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) (2019) (12)
- Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study (2010) (12)
- Switching to Bupropion in Fluoxetine-Resistant Major Depressive Disorder (2003) (12)
- Association between physician beliefs regarding assigned treatment and clinical response: re-analysis of data from the Hypericum Depression Trial Study Group. (2015) (12)
- 5HT1A-mediated stimulation of cortisol release in major depression: use of non-invasive cortisol measurements to predict clinical response (2010) (12)
- Epilepsy and the ancient world: from the magic beliefs of the Babylonians to the Hippocratic scientific thinking. (1994) (11)
- Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies (2013) (11)
- Maintaining Rapid Antidepressant Effects Following Ketamine Infusion: A Major Unmet Need. (2020) (11)
- Staging Treatment Intensity and Defining Resistant Depression: Historical Overview and Future Directions. (2019) (11)
- Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies. (2020) (11)
- Switching Antidepressants vs. Conventional Augmentation Strategies (2009) (10)
- Identifying patients with depression who require a change in treatment and implementing that change. (2016) (10)
- PS89. Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study (2015) (10)
- Monoaminergic‐based Pharmacotherapy for Depression (2005) (10)
- Does the frequency of follow-up assessments affect clinical trial outcome? A meta-analysis and meta-regression of placebo-controlled randomized trials. (2012) (9)
- Pre-treatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: A 12-week follow-up study. (2019) (9)
- The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study (2021) (9)
- Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy (2013) (9)
- Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study (2020) (9)
- PS153. Efficacy of ziprasidone monotherapy in patients with anxious depression: A 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial (2015) (8)
- Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study. (2020) (8)
- Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis (2020) (8)
- Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial (2014) (8)
- Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. (2020) (8)
- Complementary and Alternative Medicine in Major Depressive Disorder (2009) (8)
- Switching, combination, and augmentation strategies for major depressive disorder. (2010) (7)
- Inadequate Response to Antidepressant Treatment in Major Depressive Disorder. (2020) (7)
- Initial treatment approaches for patients with major depressive disorder. (2009) (7)
- Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram (2006) (6)
- Ziprasidone augmentation for anxious depression (2016) (6)
- Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression. (2016) (6)
- Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis. (2022) (6)
- Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY. (2020) (6)
- Recognizing Inadequate Response in Patients With Major Depressive Disorder. (2020) (6)
- Efficacy of Ziprasidone Augmentation of Escitalopram for Cognitive Symptoms of Major Depressive Disorder. (2017) (6)
- Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study. (2017) (6)
- A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed (2003) (6)
- Serotonin Norepinephrine Reuptake Inhibitors: Spectrum of Efficacy in Major Depressive Disorder (2009) (6)
- International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators (2022) (5)
- Examining the Evidence on Augmentation with Atypical Antipsychotics (2007) (5)
- Treatment-Related Adverse Events and Outcome in a Clinical Trial of Fluoxetine for Major Depressive Disorder (2003) (5)
- Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment (2014) (5)
- Antidepressants in children and adolescents with major depressive disorder and the influence of placebo response: A meta-analysis. (2022) (5)
- Overcoming Challenges to Treat Inadequate Response in Major Depressive Disorder. (2020) (5)
- Success and efficiency of phase 2/3 adjunctive trials for MDD funded by industry: a systematic review (2020) (5)
- Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. (2020) (4)
- Problem‐solving ability and comorbid personality disorders in depressed outpatients (2006) (4)
- Differences in cognitive factors between “true drug” versus “placebo pattern” response to fluoxetine as defined by pattern analysis (2006) (4)
- A Historical Inquiry into the Appropriateness of the Term `Panic Disorder' (2003) (4)
- L-methylfolate augmentation of selective serotonin reuptake inhibitors (SSRIS) for major depressive disorder: Results of two randomized, double-blind trials (2011) (4)
- Erratum: The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine (International Journal of Neuropsychopharmacology (2005) DOI: 10.1017/S1461145705005195) (2005) (4)
- A Double-Blind Randomized Controlled Trial of Ethyl- Eicosapentaenoate (EPA-E) for Major Depressive Disorder (2010) (4)
- 9 – Mood-Disordered Patients (2010) (4)
- Ratio of plasma BDNF to leptin levels are associated with treatment response in major depressive disorder but not in panic disorder: A 12-week follow-up study. (2019) (4)
- Implementing Measurement-Based Care to Determine and Treat Inadequate Response. (2020) (4)
- Bioavailability of S-Adenosyl Methionine and Impact on Response in a Randomized Controlled Trial in Major Depressive Disorder (2014) (3)
- P0046 - Resolution of sleepiness and fatigue: A comparison of bupropion and ssris in Patients achieving remission in MDD (2008) (3)
- Early‐onset depression and the emotional and behavioral characteristics of offspring (2003) (3)
- Diagnostic assessment of major depressive disorder. (2009) (3)
- Pharmacological Treatment of Major Depressive Disorder: A Review (2009) (3)
- P.2.f.024 Efficacy and tolerability of vortioxetine is independent of previous treatment in MDD patients switched after an inadequate response (2014) (3)
- A survey of five antidepressant properties influencing clinician’s treatment choices in MDD (2007) (3)
- Components of Cognitive Functioning and Their Measurement (2015) (2)
- Tackling partial response to depression treatment. (2009) (2)
- PMH49 COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS AS ADJUNCTIVE THERAPY IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD) (2010) (2)
- Treatment-Resistant Major Depressive Disorder: New Developments in 2006 (2006) (2)
- Novel augmentation strategies for treatment-resistant major depressive disorder (2007) (2)
- The Use of Atypical Antipsychotics as Augmentation for Treatment-Resistant Major Depressive Disorder (2008) (2)
- The response of psychotic-like symptoms to fluoxetine monotherapy in non-psychotic major depressive disorder (2009) (2)
- Reply to commentary by Rothschild: "A Blood Test for Depression?". (2015) (2)
- NSI-189 phosphate, a novel neurogenic compound, selectively benefits moderately depressed patients: A post-hoc analysis of a phase 2 study of major depressive disorder. (2020) (2)
- Comprar Pharmacotherapy for depression and treatment-resistant depression | Papakostas, G.I. | 9789814287586 | World Scientific Publishing (2010) (2)
- Update on Treatment of Depression (2014) (1)
- Chapter 8 – Mood-Disordered Patients (2004) (1)
- Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. (2022) (1)
- Reply to Fleisch et al. Letter. (2010) (1)
- Psychoticism and Paranoid Ideation in Patients With Nonpsychotic Major Depressive Disorder: Prevalence, Response to Treatment, and Impact on Short- and Long-Term Treatment Outcome (2010) (1)
- P.032 A phase-2, double-blind, placebo-controlled, sequential parallel comparison design study of efficacy and safety of adjunctive pimavanserin in major depressive disorder (2019) (1)
- Non-pharmacologic Approaches for Resistant Depression (2010) (1)
- Polypharmacy in Depression (1985) (1)
- Happiness and Treatment Outcome in Resistant Depression. (2020) (1)
- A Survey of Antidepressant Prescribing Practices in Major Depression with Comorbid Attention-Deficit Hyperactivity Disorder (2006) (1)
- Dr. Mischoulon and colleagues reply. (2014) (1)
- Biological Predictors, Moderators, and Mediators of Efficacy (2010) (1)
- Identifying Patients Who Need a Change in Depression Treatment and Implementing That Change. (2016) (1)
- 180 Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder with Adjunctive Pimavanserin (2020) (1)
- Maintaining Treatment Gains (2010) (0)
- Association of obesity and levels of Inflammatory markers on treatment outcome with adjunctive L-methylfolate (Deplin) in major depressive disorder patients who are inadequate responders to selective serotonin reuptake Inhibitors (2015) (0)
- PW01-24 - Evaluation of the Effects of Quetiapine XR Monotherapy According to MDD Severity: Pooled Data From 4 Placebo-controlled Trials (2010) (0)
- P.094 Evaluate effects of pimavanserin on anxious depression in patients with major depressive disorder - secondary analysis of the CLARITY Study (2020) (0)
- A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of S-Adenosyl- L -Methionine (SAMe) Vs. Escitalopram in Major Depressive Disorder (2017) (0)
- Major Depressive Disorder and Treatment-Resistant Depression (2010) (0)
- P.338 Effect of adjunctive pimavanserin on suicidality in patients with major depression: secondary analysis from CLARITY (2020) (0)
- Drs. Nelson and Papakostas Reply (2010) (0)
- Predictors, moderators, and mediators of symptom improvement in major depressive disorder: Overview, definition, and significance (2010) (0)
- Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis. (2022) (0)
- Pharmacologic Strategies to Enhance Antidepressant Tolerability (2010) (0)
- Monoaminergic-Based Strategies: “Single-Acting” Agents (2010) (0)
- Polypharmacy Strategies for Treatment-Resistant Depression (2010) (0)
- Faculty Opinions recommendation of Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. (2010) (0)
- C.19.02 Targeting specific symptoms in major depression (2008) (0)
- First-Line Pharmacotherapy Strategies (2010) (0)
- 181 A Phase-2 Sequential Parallel Comparison Design Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (2020) (0)
- SAT-737 Low-Dose Testosterone Augmentation for Treatment-Resistant Depression in Women: An 8-Week, Two-Site, Randomized, Placebo-Controlled Study (2020) (0)
- Reduced orbitofrontal-thalamic functional connectivity related to suicidal ideation in patients with major depressive disorder (2017) (0)
- Association of Obesity and Levels of Inflammatory Markers on Treatment Outcome with Adjunctive (6S)-5-methyl-5,6,7,8-tetrahydropteroyl-L-glutamic Acid (CH3-FH4) in MDD Patients Who are Inadequate Responders to SSRIs (2015) (0)
- Agents Operating on Non-monoaminergic Neurotransmitter Systems (2010) (0)
- P.2.c.026 Antidepressants for late-life depression: a meta analysis of placebo-controlled randomized trials (2010) (0)
- PW01-03 - Evaluation of the Effects of Quetiapine XR Monotherapy On Sleep Disturbance In Patients With MDD (2010) (0)
- Metabolic-Based and Other Agents (2010) (0)
- C.01.03 Treatment of cognitive dysfunction in clinical practice: what have we learnt from our major depressive disorder (MDD) patients? (2016) (0)
- Primer on Depression (2019) (0)
- Pharmacotherapy of Relapse/Recurrence Prevention and Treatment (2010) (0)
- C.04.01 MDD: treatment limitations and ongoing challenges (2012) (0)
- C.07.03 No time to lose: rethinking treatment options in MDD (2011) (0)
- major depressive disorder Brain white-matter hyperintensities and treatment outcome in (2011) (0)
- Future Directions in Treatment Development (2010) (0)
- Male and Female Sexual Function and Dysfunction; Andrology (2011) (0)
- Methysergide and ritanserin effects on the TRH test in depression (1993) (0)
- Monotherapy Strategies for Resistant Depression (2010) (0)
- Book Review / Announcements (2002) (0)
- Stahl's illustrated. Mood stabilizers and Stahl's illustrated. Antidepressants (2011) (0)
- P.010 Dose increase of s-adenosyl-methionine and escitalopram in a randomized clinical trial for major depressive disorder (2019) (0)
- Adjunctive Cariprazine in Patients With Major Depressive Disorder: Post Hoc Analysis of Efficacy by Baseline Antidepressant Response (2023) (0)
- Polypharmacy from the Onset of Treatment (2010) (0)
- Muscarinic Cholinergic Receptor Agonists and Antagonists (2015) (0)
- Next-Step Treatment Strategies (2010) (0)
- Predictors, moderators and mediators of symptom improvement in major depressive disorder (2010) (0)
- Deformities of the Globus Pallidus are Associated with Severity of Suicidal Ideation and Impulsivity in Patients with Major Depressive Disorder (2019) (0)
- Faculty Opinions recommendation of Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. (2009) (0)
- Antipsychotic Drugs for Depression? Authors' reply (2010) (0)
- Neuroendocrine-Based Agents (2010) (0)
- C.03.04 Integrating clinical treatment strategies for major depressive disorder (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With George I. Papakostas?
George I. Papakostas is affiliated with the following schools:
